Company Filing History:
Years Active: 2025
Title: Innovations by Daniel Jay Schneider in Lymphoma Treatment
Introduction
Daniel Jay Schneider is an accomplished inventor based in Wynnewood, PA (US). He has made significant contributions to the field of oncology, particularly in improving treatment outcomes for patients with aggressive non-Hodgkin lymphoma. His innovative approach focuses on predicting tolerability to treatments, which can help patients avoid adverse effects from conventional therapies.
Latest Patents
Daniel Jay Schneider holds a patent for a groundbreaking system and method aimed at predicting tolerability in aggressive non-Hodgkin lymphoma. This patent, which is designed to enhance the outcomes for subjects with lymphoma, allows for a more accurate prediction of which patients can tolerate specific treatments. By utilizing a machine-learning model, the method processes an input data set that includes various data values related to the patient. The result is a score that indicates the degree of tolerance a patient may have for a particular treatment, ultimately leading to better-informed treatment decisions.
Career Highlights
Daniel is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to medicine. His work at Genentech has allowed him to collaborate with other talented professionals in the field, further advancing the research and development of effective treatments for cancer.
Collaborations
Some of Daniel's notable coworkers include Tina Geritz Nielsen and Joseph Nathaniel Paulson. Their collective expertise contributes to the ongoing efforts in enhancing patient care and treatment methodologies in oncology.
Conclusion
Daniel Jay Schneider's innovative work in predicting treatment tolerability for lymphoma patients exemplifies the impact of technology and research in modern medicine. His contributions are paving the way for more personalized and effective treatment options for individuals facing aggressive non-Hodgkin lymphoma.